Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review

Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2023-04, Vol.24 (9), p.7849
Hauptverfasser:	Amati, Francesco, Stainer, Anna, Polelli, Veronica, Mantero, Marco, Gramegna, Andrea, Blasi, Francesco, Aliberti, Stefano
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials Development and progression Drugs Fibrosis Genotype & phenotype Humans Idiopathic Pulmonary Fibrosis - drug therapy Idiopathic Pulmonary Fibrosis - pathology Independent regulatory commissions Indoles - therapeutic use Lung diseases Lung Diseases, Interstitial - drug therapy Lungs Patients Phenotypes Pulmonary fibrosis Pyridones - therapeutic use Respiratory agents Review Strategic planning (Business) Systematic review Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!